ARTICLE | Company News
Biotest sales and marketing update
February 11, 2013 8:00 AM UTC
Biotest's Biotest Pharmaceuticals Corp. subsidiary launched IV Bivigam 10% human immune globulin in U.S. to treat primary immune deficiency disorders. The wholesale acquisition cost of the polyspecific IV immune globulin is $1,199.60 for a 100 mL vial of 100 mg/mL fluid. The recommended dose is 300-800 mg/kg every 3-4 weeks. ...